|
|
| VGX
Announces Promotion of Gene Kim as Chief Financial Officer
|
| Blue
Bell, PA – May 1, 2006 – |
|
J. Joseph Kim, Ph.D., President and Chief Executive
Officer of VGX Pharmaceuticals announced today the promotion of Gene Kim
to the position of Chief Financial Officer.
“Gene brings a wealth of knowledge and experience to our executive
management team," said Dr. Kim. "I am confident that his extensive
finance experience will be an invaluable asset to our company as we define
and execute our growth strategies, including our preparation for an Initial
Public Offering in near future."
Mr. Kim has served as VGX's Director of Finance since May 2005. For more
than 11 years, Mr. Kim has directed various financial functions across
several industries. He has served as a Director of Finance for a number
of high-tech start-ups in Silicon Valley, including Yodlee, a firm providing
technology solutions for the financial services industry, and Pandesic,
a joint venture between Intel and SAP. His duties included the establishment
and integration of policies and procedures, implementation of accounting
systems, and financial planning and analysis. He has also served as a
financial advisor to several small start-up companies in the Washington
DC area. Prior to Mr. Kim’s work with start-up companies, he has
worked for Bankers Trust/Deutsche Bank in New York as a trader in the
interest rate arbitrage group.
Mr. Kim received an MBA in Finance from the Wharton School of Business
at the University of Pennsylvania and a Bachelor of Science in Chemical
Engineering from University of California at Los Angeles.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About
VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2006 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Vice President
Tel 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
